Last updated: February 21, 2026
What is the Drug Associated with NDC 72888-0185?
NDC 72888-0185 corresponds to Rinvoq (upadacitinib), a Janus kinase (JAK) inhibitor for the treatment of moderate-to-severe rheumatoid arthritis (RA). Manufactured by AbbVie, Rinvoq was approved by the FDA in August 2019.
Indications:
- Rheumatoid arthritis
- Psoriatic arthritis
- Atopic dermatitis (recently expanded)
Market Landscape
Market Size and Growth
The global rheumatoid arthritis (RA) drug market was valued at approximately $17 billion in 2022. It projects a compound annual growth rate (CAGR) of 4.5% through 2030, driven by increasing prevalence, earlier diagnosis, and novel therapies.
Key Market Segments:
- Biologic Disease-Modifying Antirheumatic Drugs (bDMARDs): $10B in 2022, including Humira, Enbrel, and Skyrizi.
- Targeted Synthetic DMARDs (tsDMARDs): includes JAK inhibitors like Rinvoq and Olekris.
- Oral JAK Inhibitors: Rinvoq and Pfizer's Xeljanz.
Rinvoq’s Competitive Position
Rinvoq's entry in the JAK inhibitor market offers a more selective profile compared to Xeljanz (tofacitinib). It targets RA patients who have failed initial biologic therapy and is expanding into other indications.
Market Penetration
- In 2022, Rinvoq accounted for approximately 15% of the JAK inhibitor segment in RA.
- It trails Xeljanz, which holds roughly 55% market share.
- Growth drivers include favorable efficacy data, low oral bioavailability, and expanding indications.
Price Analysis and Projections
Current Pricing (2023)
- Wholesale Acquisition Cost (WAC): Approximately $5,000 - $6,000 per month (per 30-day supply).
- Average Selling Price (ASP): Estimated at $4,700 per month, factoring discounts and rebates.
- Annual Cost: Approximately $56,400 - $72,000 per patient.
Cost Drivers
- Manufacturing costs are estimated to be around 10-15% of WAC, indicating significant price premiums.
- Payers negotiate substantial rebates, reducing net prices.
- Clinical benefits and patent exclusivity influence pricing stability.
Price Trends (2023-2028)
| Year |
Estimated Wholesale Price |
Key Factors |
| 2023 |
$5,000 - $6,000/month |
Market equilibrium, patent protection holds; no major biosimilar threats |
| 2024 |
Slight increase to $5,200 - $6,200 |
Competition intensifies with biosimilar influx for comparators, but JAK inhibitors maintain premium status |
| 2025 |
Stabilization or slight decrease, $5,100 - $6,000 |
Payer negotiations increase due to biosimilar entries for biologics; Rinvoq maintains differentiation |
| 2026 |
Possible reduction, $4,900 - $5,800 |
Potential biosimilar competition for RA biologics; Rinvoq's exclusivity lapses or faces patent challenges |
| 2027 |
Price stabilization at $4,800 - $5,700 |
Market saturation; competitive discounts drive prices down |
Impact of Patent Expiry
- Patents for Rinvoq are expected to expire around 2030.
- Biosimilar or generic entry anticipated a few years prior with potential price erosion of 20-30%.
Cost-Effectiveness and Pricing Power
- Clinical trial data demonstrate superior efficacy over some biologics in specific populations.
- Such data sustain premium pricing.
- Payer-restrictive formularies and tiered copayments constrain market share expansion.
Market Dynamics & Future Opportunities
- Expansion Into New Indications: Atopic dermatitis, ankylosing spondylitis, UC.
- Combination Therapies: Increasing use with other DMARDs.
- Global Market: Rising prevalence in Asia-Pacific, with price sensitivity influencing adoption.
Key Considerations for Stakeholders
- Manufacturers should monitor patent protections and biosimilar developments.
- Investors should analyze payer policies and formulary trends impacting reimbursement.
- R&D efforts focusing on improved formulations or oral JAK inhibitors could affect pricing trajectories.
Summary
| Aspect |
Details |
| Market Size |
$17B globally (2022), CAGR 4.5% till 2030 |
| Current Price |
$5,000–$6,000 monthly WAC |
| Market Share |
Rinvoq ~15% in JAK RA segment |
| Price Outlook |
Stable with potential slight decrease circa 2025, potential erosion post-2030 due to biosimilars |
Key Takeaways
- Rinvoq’s current pricing aligns with premium biologics based on efficacy.
- Market penetration faces near-term limits from biosimilar competition.
- Future pricing depends on patent status, biosimilar entries, and expanding indications.
- Overall market growth supports a positive outlook for Rinvoq-related revenues, provided patent protections hold.
5 FAQs
- What factors influence Rinvoq’s pricing stability? Patent protections and clinical efficacy sustain premium pricing; biosimilar competition and payer negotiations can cause price pressure.
- When are biosimilars expected to impact Rinvoq’s market share? Biosimilars for biologic RA agents likely to emerge around 2028-2030, influencing Rinvoq's market share.
- Will expanding indications affect pricing? Yes, new approved uses can justify price increases or maintain premiums.
- How does Rinvoq compare price-wise to Xeljanz? Rinvoq’s monthly cost is roughly 10-20% higher, reflecting its differentiated profile.
- What emerging trends could alter price projections? Entry of oral JAK inhibitors with improved profiles or regulatory changes affecting patent enforcement.
References
[1] IQVIA. (2023). Pharmaceutical Market Outlook.
[2] FDA. (2019). FDA approves Rinvoq for rheumatoid arthritis.
[3] GlobalData. (2022). RA Market Insights.
[4] SSR Health. (2023). Estimated net prices for biologics and small molecules.
[5] EvaluatePharma. (2023). World Preview 2023.
